Axalta Coating Systems
AXTA
$33.61
-2.97%
Axalta Coating Systems Ltd. is a global manufacturer, marketer, and distributor of high-performance coatings systems, operating through two segments: Performance Coatings (refinish and industrial liquid and powder coatings) and Mobility Coatings (coatings for light and commercial vehicle OEMs), with the majority of revenue generated from Mobility Coatings and the largest geographic contribution from EMEA. The company occupies a leading position in the specialty chemicals coatings space, distinguished by its entrenched relationships with automotive OEMs and a fragmented, service-intensive refinish aftermarket that provides recurring revenue and pricing power. The current investor narrative centers on the durability of refinish demand, the cyclical recovery trajectory of automotive production volumes, and management's ability to expand margins through raw-material normalization and cost discipline. With a market capitalization of roughly $6.6 billion, a beta of 1.24, and a forward P/E near 11x against a trailing P/E of 18.5x, the debate is whether the market is underappreciating the earnings recovery implied by consensus estimates or correctly discounting cyclical and competitive risks.…
AXTA
Axalta Coating Systems
$33.61
Investment Opinion: Should I buy AXTA Today?
The synthesized recommendation is a Hold with a bullish bias, reflecting a compelling valuation case offset by severe near-term momentum deterioration and cyclical uncertainty. The core thesis is that AXTA's forward P/E of 11.21x and consensus analyst target of $39.33 (+22.2% upside) offer an attractive risk/reward for patient investors willing to look through a cyclical trough, but the stock's -15.28% YTD relative underperformance and -10.03% one-month decline suggest the market is not yet ready to reward the recovery story. The consensus 'buy' rating (mean 2.19 from 15 analysts) anchors the positive view, but the wide target range of $33.00 to $47.00 signals significant disagreement about the pace and magnitude of the earnings rebound.
Supporting evidence for the Hold rating includes: (1) the forward P/E of 11.21x versus trailing 18.46x implies a 39% earnings growth expectation that, if realized, would make the stock cheap; (2) the EV/EBITDA of 9.39x is moderate for a specialty chemicals company and below the 10x threshold; (3) ROE of 16.11% demonstrates efficient capital deployment despite a debt-to-equity of 1.45; and (4) the price-to-cash-flow of 10.75x suggests cash generation is reasonably valued. However, the gross margin of 32.64% and net margin of 7.39% are not exceptional, and the lack of a dividend (0% yield) means total return depends entirely on multiple expansion and earnings delivery.
The biggest risks that could invalidate the thesis are: (1) a failure to achieve the consensus EPS of $3.47, which would collapse the forward P/E argument; (2) a breakdown below the 52-week low of $24.94, which would confirm a bearish trend reversal; and (3) further relative underperformance versus the S&P 500, which could trigger analyst downgrades. This Hold would upgrade to Buy if the stock stabilizes above $30 and forward estimates hold, or if the forward P/E compresses below 10x on unchanged estimates. It would downgrade to Sell if revenue growth turns negative or if the stock breaks below $24.94 on high volume. Relative to its own history and the moderate EV/EBITDA, AXTA appears fairly valued to slightly undervalued, but the market is demanding proof of the earnings recovery before re-rating the multiple.
Sign up to view all
AXTA 12-Month Price Forecast
The forward-looking view is cautiously neutral: the valuation is compelling if consensus estimates are met, but the market is clearly skeptical given the severe relative underperformance and deteriorating momentum. The 11.21x forward P/E and $39.33 average target imply significant upside, yet the stock's inability to sustain gains above $38 suggests deep-seated concerns about cyclical demand and leverage. I would upgrade to bullish if the company reports two consecutive quarters of EPS growth toward the $3.47 annual estimate and gross margins expand above 34%. I would downgrade to bearish if the stock breaks below $28 on high volume or if analysts begin cutting the $3.47 EPS estimate, which would undermine the entire forward valuation case.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axalta Coating Systems's 12-month outlook, with a consensus price target around $39.00 and implied upside of +16.0% versus the current price.
Average Target
$39.00
0 analysts
Implied Upside
+16.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$33 - $47
Analyst target range
AXTA is covered by 15 analysts, and the consensus recommendation is "buy" with a recommendation mean of 2.19 on what appears to be a 1-to-5 scale (where lower is more bullish). The average target price is $39.33, which against the current price of $32.20 implies approximately +22.2% upside to consensus. This is a meaningfully bullish signal: the consensus target sits above the 52-week high of $38.61, indicating that analysts collectively expect the stock to break out to new highs over the coming year, and the buy-leaning distribution suggests the sell-side views the recent 10% one-month decline as a buying opportunity rather than the start of a sustained downtrend.
The target range spans from a low of $33.00 to a high of $47.00, a spread of $14.00, or roughly 42% of the average target, which signals moderate-to-high uncertainty among analysts. The low target of $33.00 implies only about +2.5% upside and likely assumes flat-to-modest earnings growth with stable margins and no multiple expansion, essentially a "hold" scenario. The high target of $47.00 implies roughly +46% upside and likely prices in a full cyclical recovery, margin expansion toward the high end of historical ranges, and possibly multiple re-rating as the market gains confidence in the earnings trajectory; the consensus EPS estimate of $3.47 (with a tight range of $3.41 to $3.54) suggests analysts are aligned on near-term earnings but diverge on the appropriate multiple. The relatively tight EPS estimate band combined with the wide price target range indicates that the debate is about valuation multiple and terminal growth assumptions rather than near-term earnings delivery.
Bulls vs Bears: AXTA Investment Factors
The bear case currently has stronger near-term evidence due to severe relative underperformance (-15.28% YTD vs. SPY +12.86%) and deteriorating momentum (-10.03% over one month), which suggest the market is skeptical of the earnings recovery implied by the 11.21x forward P/E. However, the bull case rests on a compelling valuation gap: the 39% trailing-to-forward P/E compression and a consensus analyst target of $39.33 (+22.2% upside) indicate that if earnings materialize as expected, the stock is significantly undervalued. The single most important tension is whether the consensus EPS estimate of $3.47 is achievable; if it is, the forward multiple is unsustainably low, but if estimates are cut, the stock could retest its 52-week low of $24.94. The debate hinges on the durability of the automotive production recovery and refinish demand, with the market currently pricing in doubt.
Bullish
- Deep Forward P/E Discount: AXTA trades at a forward P/E of 11.21x versus a trailing P/E of 18.46x, a 39% compression that implies the market expects earnings to grow substantially. Consensus EPS estimates of $3.47 against the current $32.20 price produce this low multiple, suggesting the stock is priced for a cyclical earnings recovery rather than steady-state performance.
- Analyst Consensus Sees 22% Upside: All 15 covering analysts have a consensus 'buy' rating (mean 2.19) with an average target price of $39.33, implying +22.2% upside from the current price. The average target sits above the 52-week high of $38.61, indicating analysts expect the stock to break out to new highs over the next year.
- Strong ROE Despite Leverage: AXTA generates a 16.11% return on equity and a 6.12% return on assets, demonstrating efficient capital deployment despite a debt-to-equity ratio of 1.45. The current ratio of 2.06 provides ample short-term liquidity, and the price-to-cash-flow of 10.75x suggests cash generation is reasonably valued.
- Moderate EV/EBITDA for Specialty Chemicals: The EV/EBITDA of 9.39x is below the 10x threshold often considered moderate for a capital-intensive specialty chemicals business with mid-single-digit growth prospects. This valuation does not appear to price in exceptional returns, leaving room for multiple expansion if earnings recover as expected.
Bearish
- Severe Relative Underperformance: AXTA has underperformed the S&P 500 by 10.62% over the past month, 11.63% over three months, and 15.28% year-to-date, even as SPY gained 12.86% YTD. This persistent negative relative strength signals that the market is actively de-rating the stock despite the broader market rally.
- Elevated Leverage Amplifies Risk: The debt-to-equity ratio of 1.45 is elevated for a specialty chemicals company, and with a net margin of only 7.39%, the company has limited cushion to absorb rising interest costs or a demand downturn. High leverage means consistent cash generation is required to service obligations, leaving less margin for error.
- Momentum Breakdown and Short Pressure: The 1-month change of -10.03% and 3-month change of -8.29% contrast sharply with the 1-year gain of +14.22%, indicating a clear loss of upside momentum. A short ratio of 4.84 shows bearish positioning has built up, and the stock is vulnerable to further downside if support near $24.94 fails.
- Thin Margins Limit Pricing Power: A gross margin of 32.64% and net margin of 7.39% are respectable but not top-tier for specialty chemicals, suggesting limited pricing power relative to premium peers. The 14.93% operating margin indicates decent cost control but leaves room for improvement only if volumes recover meaningfully.
AXTA Technical Analysis
AXTA is in a medium-term recovery that has stalled, with the stock up 14.22% over the past year but down 2.42% year-to-date, and currently trading at $32.20, which is approximately 52.9% of its 52-week range (52-week low of $24.94 and high of $38.61). This mid-range positioning reflects a market that has neither fully embraced nor abandoned the recovery story: the stock is well above its lows but has failed to sustain the momentum that carried it to the upper $30s in August. The 6-month change of +20.06% confirms that the dominant intermediate trend was upward, but the recent stall suggests the stock is digesting those gains rather than extending them.
Short-term momentum has deteriorated sharply and is diverging from the longer-term trend. The 1-month change of -10.03% and 3-month change of -8.29% contrast starkly with the 1-year gain of +14.22%, signaling a clear loss of upside momentum and a potential trend reversal if support fails. Relative strength versus the S&P 500 is deeply negative across the 1-month (-10.62%), 3-month (-11.63%), and YTD (-15.28%) windows, meaning AXTA is significantly underperforming the broader market even as SPY has gained 0.59% over the past month and 12.86% YTD. This persistent underperformance, combined with a short ratio of 4.84, indicates that bearish positioning has built up and that the stock is vulnerable to further downside unless a catalyst reverses sentiment.
Key technical levels are well defined: support sits near the 52-week low of $24.94, while resistance is anchored at the 52-week high of $38.61, with the recent August peak around $38.19 acting as an intermediate ceiling. A breakout above $38.61 would signal a resumption of the primary uptrend and likely force short covering, while a breakdown below $24.94 would confirm a bearish trend reversal and open the door to new lows. With a beta of 1.239, AXTA is roughly 24% more volatile than the market, meaning position sizing should account for amplified moves in both directions; the maximum drawdown of -28.48% over the period underscores that this is not a low-volatility holding.
Beta
1.26
1.26x market volatility
Max Drawdown
-28.5%
Largest decline past year
52-Week Range
$25-$39
Price range past year
Annual Return
+14.0%
Cumulative gain past year
| Period | AXTA Return | S&P 500 |
|---|---|---|
| 1m | +3.0% | +0.7% |
| 3m | -6.1% | +3.0% |
| 6m | +21.2% | +6.8% |
| 1y | +14.0% | +11.9% |
| ytd | +1.8% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXTA Fundamental Analysis
Revenue trajectory data is not available in the provided quarterly financials, income statement, or revenue segment disclosures, so a multi-quarter growth analysis cannot be constructed from the inputs. However, consensus analyst estimates project average revenue of approximately $5.47 billion for the forward period, with a range of $5.40 billion to $5.55 billion, implying a relatively stable top-line outlook with limited variance across the analyst community. The narrow revenue estimate band suggests analysts see the business as mature and predictable rather than a high-growth story, which is consistent with a specialty coatings company levered to automotive production and refinish demand cycles.
Profitability metrics indicate a solidly profitable but not exceptional business. The company reports a net margin of 7.39%, a gross margin of 32.64%, and an operating margin of 14.93%, with an EPS of $0.054 (likely a quarterly figure) and an ROE of 16.11%. The spread between the 32.64% gross margin and 14.93% operating margin implies meaningful operating expense absorption, while the 7.39% net margin reflects the impact of interest costs and taxes on a leveraged balance sheet. For a specialty chemicals company, a gross margin in the low-30s is respectable but not top-tier, suggesting limited pricing power relative to premium chemical peers, and the 14.93% operating margin indicates decent cost control but room for improvement if volumes recover.
Balance sheet and cash flow analysis is constrained by the absence of cash flow statements and detailed financial ratios, but available metrics paint a mixed picture. The debt-to-equity ratio of 1.45 is elevated and indicates meaningful financial leverage, which amplifies both returns and risk; the current ratio of 2.06, however, signals ample short-term liquidity to cover near-term obligations. The price-to-cash-flow ratio of 10.75 suggests the company generates cash flow that is reasonably valued relative to its market cap, and the ROE of 16.11% demonstrates that management is generating acceptable returns on shareholder capital despite the leverage. The combination of high debt and moderate profitability means AXTA depends on consistent cash generation to service obligations, leaving less margin for error if end markets weaken.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXTA Overvalued?
Because net income is positive (net margin of 7.39%, EPS of $0.054), the P/E ratio is the appropriate primary valuation metric. AXTA trades at a trailing P/E of 18.46x and a forward P/E of 11.21x, a dramatic 39% compression that implies the market expects earnings to grow substantially over the next twelve months. This gap is corroborated by consensus EPS estimates of $3.47, which, against the current price of $32.20, produces the 11.21x forward multiple; the market is clearly pricing in a significant earnings recovery rather than steady-state performance.
Peer comparison data for the specialty chemicals industry is not provided in the valuation dataset, so a direct sector-average comparison cannot be quantified. However, the stock's price-to-sales ratio of 1.36x and EV/EBITDA of 9.39x are the more relevant cross-checks for a capital-intensive coatings business; an EV/EBITDA below 10x is generally considered moderate for a specialty chemicals company with mid-single-digit growth prospects. The price-to-book ratio of 2.97x suggests the market values the franchise at roughly three times book, which is reasonable for a company with a 16.11% ROE but not a premium multiple, implying the market is not pricing in exceptional returns on capital.
Historical ratio data is not available in the provided inputs, so the current valuation cannot be positioned within the stock's own historical PE or PS band. That said, the forward P/E of 11.21x versus the trailing 18.46x is itself a strong signal: the market is applying a low multiple to forward earnings, which historically tends to occur either when earnings are cyclically depressed and expected to rebound, or when the market doubts the sustainability of those estimates. The negative PEG ratio of -10.95 (a mechanical artifact of the calculation methodology) and the absence of a dividend (payout ratio of 0, dividend yield of 0) mean total return depends entirely on earnings growth and multiple re-rating, with no income cushion for investors.
PE
18.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.4x
Enterprise Value Multiple
Investment Risk Disclosure
AXTA's financial risk profile is dominated by its elevated leverage, with a debt-to-equity ratio of 1.45 that amplifies both returns and vulnerability. The net margin of 7.39% and operating margin of 14.93% provide only a modest buffer to absorb rising interest costs or a demand downturn, and the absence of a dividend (payout ratio of 0) means there is no income cushion for investors. While the current ratio of 2.06 signals adequate short-term liquidity, the company depends on consistent cash generation to service its debt, leaving limited margin for error if end markets weaken or raw material costs spike again.
Market and competitive risks are significant given AXTA's beta of 1.239, meaning the stock is roughly 24% more volatile than the broader market and highly sensitive to macroeconomic shifts. The stock has severely underperformed the S&P 500 across all recent windows, with relative strength of -10.62% over one month and -15.28% YTD, indicating that sector rotation or company-specific concerns are driving capital away. Competitive pressures in the specialty coatings space, particularly from larger diversified chemical companies with greater scale and pricing power, could compress margins further, while the cyclical nature of automotive OEM production exposes Mobility Coatings revenue to demand shocks.
The worst-case scenario would involve a synchronized global automotive production slowdown combined with raw material cost inflation and multiple compression, causing earnings to miss the consensus $3.47 EPS estimate. In this scenario, the stock could retest its 52-week low of $24.94, representing a decline of approximately -22.5% from the current price of $32.20, or fall toward the analyst low target of $33.00 (which offers only +2.5% upside and likely assumes flat growth). A more severe downturn, similar to the maximum drawdown of -28.48% observed over the period, would imply a price near $23.03, a loss of about -28.5% from current levels. Investors should note that the high short ratio of 4.84 could accelerate downside if negative catalysts emerge, as short sellers add pressure.
FAQ
The most severe risk is financial: a debt-to-equity ratio of 1.45 combined with a net margin of only 7.39% leaves limited cushion to absorb a demand downturn or rising interest costs. Second is cyclical risk: the Mobility Coatings segment is tied to automotive OEM production, and a global slowdown could cause earnings to miss the $3.47 consensus, triggering a retest of the $24.94 low. Third is competitive risk: a gross margin of 32.64% suggests limited pricing power relative to larger diversified chemical peers, and share loss in the refinish aftermarket would pressure margins. Fourth is market risk: with a beta of 1.239 and a short ratio of 4.84, the stock is 24% more volatile than the market and vulnerable to accelerated selling if sentiment deteriorates further.
The 12-month forecast is distributed across three scenarios: a base case (55% probability) targeting $36-$40, aligned with the analyst average of $39.33, assuming the consensus EPS of $3.47 is met; a bull case (25% probability) targeting $42-$47, requiring margin expansion and a multiple re-rating to 13-14x forward earnings; and a bear case (20% probability) targeting $24-$30, driven by earnings misses and a breakdown below the 52-week low of $24.94. The most likely scenario is the base case, which assumes revenue of approximately $5.47 billion and stable operating margins near 15%. The key assumption behind this forecast is that automotive production volumes normalize gradually without a global recession, allowing the company to deliver on its earnings estimates.
AXTA appears undervalued on a forward earnings basis, trading at a forward P/E of 11.21x versus a trailing P/E of 18.46x, a 39% compression that implies the market expects significant earnings growth. The price-to-sales ratio of 1.36x and EV/EBITDA of 9.39x are moderate for a capital-intensive specialty chemicals company, and the price-to-book of 2.97x is reasonable given the 16.11% ROE. However, the market is clearly applying a discount due to cyclical concerns and leverage (debt-to-equity of 1.45), as evidenced by the stock's -15.28% YTD relative underperformance. The valuation implies the market expects the consensus EPS of $3.47 to be achieved but is not willing to pay a premium multiple until there is evidence of sustained margin expansion and volume recovery.
From a risk/reward perspective, AXTA offers a favorable asymmetry for patient investors: the consensus target of $39.33 implies +22.2% upside, while the 52-week low of $24.94 implies -22.5% downside, roughly balanced but with the upside supported by a forward P/E of only 11.21x. The 15-analyst consensus is 'buy' with a mean of 2.19, and the EV/EBITDA of 9.39x is moderate for specialty chemicals, suggesting the stock is not expensive. However, the severe relative underperformance (-15.28% YTD vs. SPY +12.86%) and high short ratio of 4.84 indicate that near-term sentiment is negative and further downside is possible. It is a good buy for investors with a 12-18 month horizon who believe the consensus EPS of $3.47 is achievable, but it is not suitable for those seeking income (0% dividend yield) or low volatility (beta 1.239).
AXTA is better suited for medium-to-long-term investment (12-18 months minimum) rather than short-term trading, given the cyclical nature of its end markets and the need for the earnings recovery to materialize. The stock's beta of 1.239 and maximum drawdown of -28.48% make it too volatile for short-term traders seeking stability, and the absence of a dividend (0% yield) means there is no income to offset price fluctuations. The forward P/E of 11.21x and consensus target of $39.33 suggest that patient investors could be rewarded if the company delivers on the $3.47 EPS estimate, but the severe relative underperformance (-15.28% YTD) indicates that timing is uncertain. A minimum holding period of 12-18 months is recommended to allow the cyclical recovery to play out and for the market to re-rate the multiple.